Kirsten Gordon

Experienced Clinical Trials Professional with over 5 years of expertise in managing and coordinating oncology, vaccine, and general medication trials. Proven track record as a Data Manager, Clinical Trials Coordinator, and Site Manager. Currently contributing to the success of clinical trials at IQVIA. Adept at ensuring compliance with regulatory standards, fostering strong relationships with stakeholders, and optimizing trial processes for successful outcomes.

· Informed choice Intervention for Colorectal Cancer Screening; Sponsor Exact Sciences

· Roche Cancer Screening Collection Study; Sponsor Roche- Site Manager and Lead CRC

· A Phase1/2 Randomized, Observer-blind, Active-Control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA- based Influenza and SARS-CoV2 Multi-component Vaccines in Healthy Adults; Sponsor Moderna

· A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)- Sponsored by Novartis

· A Phase IV Study to Assess the Effect of Naltrexone Hydrochloride Extended Release (ER) and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on the Occurrence of Major Adverse Cardiovascular Events; Sponsor Currax

· A Phase 1/2, randomized, observer-blind, dosefinding/dose-confirmation study to evaluate the safety, reactogenicity and immunogenicity of the mRNA-based investigational pandemic H5 influenza vaccine candidate administered in healthy younger and older adults; Sponsor GSK

• Phase II Study of Organ Preservation in Early Rectal Cancer Patients; Sponsored by Fox Chase Cancer Center- Coordinator

• Gemcitabine & Nab-Paclitaxel w/5-Fluorouracil, Leucovorin Liposomal Irinotecan in Older Patients (GIANT), Sponsored by ECOG-ACRIN, Coordinator

• Phase I Study of Neoadjuvant Pulsed Low Dose Rate Radiation with Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer, Sponsored by Fox Chase Cancer Center

• INCB054828 vs Chemo in Unresectable or Metastatic Cholangiocarcinoma with FGFR2, Sponsored by Incyte, Coordinator

• A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation, Sponsored by Alliance, Coordinator

• Study of Nivolumab or Placebo in with Resected Lower Esophageal or Gastroesophageal Junction, Sponsored by Bristol Myers Squibb, Coordinator

● A Randomized Phase II Study of Adjuvant Sunitinib or Valproic Acid in High-Risk Patients with Uveal Melanoma; Sponsored by Thomas Jefferson University and Pfizer –Lead Data Manager

● APG-115-US-002 A Phase Ib/II study of APG-115 in combination with Pembrolizumab in patients with unresectable or Metastatic Melanomas or Advanced Solid Tumors; Sponsored by Ascentage Pharma Group Inc. – Lead Data Manager

● Verastem: A Phase II trial of Defactinib (VS-6063) combined with VS-6766 (CH5126766) in patients with metastatic uveal melanoma; Sponsored by Thomas Jefferson University - Lead Data Manger

● Delcath: A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy,

Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with

Hepatic-Dominant Ocular Melanoma – Lead Data Manager